SCHEMBL5863352

SCHEMBL5863352

CN(C)C=Cc1nn2c(Cl)ccc2c(=O)n1Cc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 4/20 0.42
HPGD P15428 4/20 0.39
GAA P10253 1/20 0.39
ALDH1A1 P00352 5/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPT P10636 1/20 0.38
TDP1 Q9NUW8 1/20 0.36
FGFR1 P11362 1/20 0.36
FGFR3 P22607 1/20 0.36
TP53 P04637 1/20 0.36
PIK3CA P42336 1/20 0.36
CFTR P13569 1/20 0.36
BRD4 O60885 1/20 0.35
KDM4A O75164 1/20 0.35
TSHR P16473 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD17B10 Q99714 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5863491 1.00 KIF11 (0.42) KIF11HPGDGAAALDH1A1SMN1; SMN2
SCHEMBL5863128 0.83 KIF11 (0.42) KIF11HPGDALDH1A1SMN1; SMN2KDM4E
SCHEMBL5863538 0.77 KIF11 (0.48) KIF11HPGDALDH1A1KDM4ETDP1
SCHEMBL5863118 0.76 KIF11 (0.44) KIF11HPGDGAAALDH1A1SMN1; SMN2
SCHEMBL5863114 0.76 KIF11 (0.44) KIF11HPGDGAAALDH1A1SMN1; SMN2
SCHEMBL7102886 0.69 KIF11 (0.42) KIF11HPGDGAAALDH1A1SMN1; SMN2
SCHEMBL5863203 0.68 KMT2A (0.39) KIF11HPGDGAAALDH1A1SMN1; SMN2
SCHEMBL5863800 0.67 KIF11 (0.55) KIF11HPGDALDH1A1KDM4ETDP1
SCHEMBL5863209 0.67 KIF11 (0.56) KIF11HPGDALDH1A1KDM4ETDP1
SCHEMBL5863442 0.67 KIF11 (0.56) KIF11HPGDALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030118-B2 Pyrrolotriazinone compounds and their use to treat diseases BRISTOL-MYERS SQUIBB COMPANY (US) 2006-04-18 US disclosed
US-20030232832-A1 Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents BRISTOL-MYERS SQUIBB COMPANY 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232832-A1 Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents CCNB1, NUMA1, CCNA1 KIF11 858/4885HPGD 1725/4885GAA 2298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.